Ohtuvayre (Ensifentrine) - Effects and efficacy of Ensifentrine

Ohtuvayre (Ensifentrine) - Ensifentrine is a phosphodiesterase inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. COPD is characterized by progressive airflow obstruction and chronic inflammation of the airways. Since PDE3 and PDE4 are expressed in airway smooth muscle, inflammatory cells, and bronchial epithelial cells to drive inflammation and bronchial muscle tone, these two PDE isoforms have been identified as therapeutic targets in the treatment of COPD.

Ohtuvayre is a drug that selectively inhibits the PDE3 and PDE4 enzymes. PDE3 mainly hydrolyzes the second messenger molecule cyclic adenosine monophosphate (cAMP) in airway smooth muscle and regulates muscle tone. PDE3 can also hydrolyze cyclic guanosine monophosphate (cGMP). PDE4 regulates only cAMP and is involved in inflammatory cell activation and migration, as well as cystic fibrosis transmembrane conductance regulator (CFTR) stimulation in bronchial epithelial cells. Dual inhibition of PDE3 and PDE4 results in the accumulation of intracellular cAMP and/or cGMP levels, resulting in a synergistic effect in contracting airway smooth muscle and suppressing inflammatory responses.

Ensifentrine, the main ingredient in Ohtuvayre, can cause bronchiectasis in chronic obstructive pulmonary disease and asthma. Ohtuvayre has been shown to mediate anti-inflammatory effects by reducing levels of pro-inflammatory cytokines such as granulocyte-macrophage colony-stimulating factor [GM-CSF] in cystic fibrosis bronchial epithelial cells. In vitro, Ohtuvayre activates CFTR-mediated chloride secretion in bronchial epithelial cells, increases ciliary beat frequency, and may enhance mucociliary clearance. In a guinea pig model, Ohtuvayre showed bronchoprotective properties against airway constriction induced by spasmodogens and antigens: it induced a dose-dependent relaxation of the airways.

Reference materials:https://go.drugbank.com/drugs/DB16157